Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase
The cyclin-dependent kinase (CDK) family of proteins play prominent roles in transcription, mRNA processing, and cell cycle regulation, making them attractive cancer targets. Palbociclib was the first FDA-approved CDK inhibitor that non-selectively targets the ATP binding sites of CDK4 and CDK6. In...
Guardado en:
Autores principales: | Sandeep Rana, Jayapal Reddy Mallareddy, Sarbjit Singh, Lidia Boghean, Amarnath Natarajan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/99d03c92392341989cb9e45c2edd63ef |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Potential application of proteolysis targeting chimera (PROTAC) modification technology in natural products for their targeted protein degradation
por: Guliang Yang, et al.
Publicado: (2022) -
Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2− metastatic breast cancer: a focus on ribociclib
por: Edessa D, et al.
Publicado: (2017) -
Correlación microbiológica en cultivo de adenoides y glue en pacientes con OME
por: Pinto C,Rodrigo, et al.
Publicado: (2012) -
ERα-Targeting PROTAC as a Chemical Knockdown Tool to Investigate the Estrogen Receptor Function in Rat Menopausal Arthritis
por: Li Duan, et al.
Publicado: (2021) -
Glue and glide: a novel technique for pterygium conjunctival autograft
por: Tappin MJ, et al.
Publicado: (2018)